SCYNEXIS, Inc.
corporate_fare Company Profile
SCYNEXIS, Inc. (NASDAQ:SCYX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for SCYX at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- SCYNEXIS Completes 'Transformative' Acquisition of Innovative ADPKD Drug PXL-770
- Scynexis Reports $20.6M Revenue, Cuts Loss to $(0.17) EPS on Strategic GSK Deal
- SCYNEXIS Secures $24.8M from GSK, Advances Lead Antifungal Program SCY-247, and Extends Nasdaq Compliance
Financial Snapshot
Fiscal year ended December 31, 2025
Revenue
$20.6M
Net Income
-$8.61M
Diluted EPS
-$0.17
Op. Cash Flow
-$5.28M
Operating Income
-$16.07M
Cash & Equivalents
$21.26M
Debt / Equity
0.00×
Net Margin
-41.8%
Shares Outstanding
43.54M sh
Source: 10-K · filed 2026-03-04 · accession 0001178253-26-000007
show_chartPrice Chart
Loading chart...
feed SCYX - Filings & News (Page 2)
SCYX
Mar 31, 2026, 6:40 AM EDT
Price at Filing:
$0.7897
Real-time Price:
$2.38
Change:
Reverse Stock Split
Market Cap:
$23.689M
SCYX
Mar 04, 2026, 4:05 PM EST
Price at Filing:
$0.7752
Real-time Price:
$2.38
Change:
Reverse Stock Split
Market Cap:
$23.689M
SCYX
Mar 04, 2026, 4:01 PM EST
Price at Filing:
$0.775
Real-time Price:
$2.38
Change:
Reverse Stock Split
Market Cap:
$23.689M